Brief: Editas Medicine And Vertex Pharmaceuticals Enter Into Non-Exclusive License Agreement For Cas9
13/12/2023 14:02
Dec 13 (Reuters) - Editas Medicine Inc EDIT.O :
* EDITAS MEDICINE AND VERTEX PHARMACEUTICALS ENTER INTO
NON-EXCLUSIVE LICENSE AGREEMENT FOR CAS9
* EDITAS MEDICINE INC: VERTEX PHARMACEUTICALS TO OBTAIN A
NON-EXCLUSIVE LICENSE FOR CAS9 FOR CASGEVY
* EDITAS MEDICINE INC: AGREEMENT EXTENDS EDITAS MEDICINE'S
CASH
RUNWAY INTO 2026
Source text for Eikon: ID:nGNX1bBzDJ
Further company coverage: EDIT.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Editas Medicine
See all newsEditas Medicine, Inc. reports results for the quarter ended June 30 - Earnings Summary
Editas Medicine, Inc. expected to post a loss of 27 cents a share - Earnings Preview
Editas Medicine Q2 net loss narrows and beats estimates
Brief: Editas Medicine Q2 Net Income USD -18.23 Million Vs. IBES Estimate USD -27 Million
Editas Medicine down after $125 mln stock-and-warrants offering